MEDSNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
DataMeds AI, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$2.67+0.04 (+1.52%)
Close on Oct 19, 2026
- Market cap
- $6.87M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1.7%
0M of 3M shares
Institutional holders
10
10 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MEDS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 20,532 | 0.67% | $63.65K | New | 0.00% |
| Geode Capital Management, LLC | 12,467 | 0.41% | $38.65K | New | 0.00% |
| Vanguard Capital Management LLC | 11,085 | 0.36% | $34.36K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 6,191 | 0.20% | $19.19K | New | 0.00% |
| Barclays PLC | 723 | 0.02% | $2.24K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 678 | 0.02% | $2.10K | New | 0.00% |
| Fortitude Family Office, LLC | 118 | 0.00% | $366 | New | 0.00% |
| Integrated Wealth Concepts LLC | 25 | 0.00% | $78 | New | 0.00% |
| Global Retirement Partners, LLC | 2 | 0.00% | $6 | New | 0.00% |
| Danske Bank A/S | 1 | 0.00% | $3 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 0M | 1.7% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MEDS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 9,385 | 0.31% | $32.10K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 9,059 | 0.30% | $28.08K | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,026 | 0.07% | $6.28K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 1,507 | 0.05% | $5.15K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 947 | 0.03% | $3.24K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 607 | 0.02% | $2.08K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Prashant Patel | Chief Executive Officer, Director | 9,354,365 | 305.51% | Jun 25, 2026 |
| Srinivas Kalla | Chief Information Officer | 293,333 | 9.58% | Apr 24, 2025 |
| Mark DiSiena | Chief Financial Officer | – | – | Apr 23, 2025 |
| Brian Norton | Chief Executive Officer | 11,524,308 | 376.38% | Mar 25, 2025 |
| Nikul Panchal | Chief Pharmacy Officer | 375,761 | 12.27% | Mar 25, 2025 |
| Shafaat Pirani | Chief Clinical Officer | 102,080 | 3.33% | Mar 25, 2025 |
| Surendra K. Ajjarapu | Director | 15,445,447 | 504.44% | Jun 25, 2026 |
| Gary L. Herman | Director | – | – | Apr 10, 2026 |
| Eric Michael Sherb | Director | – | – | Apr 9, 2026 |
| Marlene Velez | Director | – | – | Apr 2, 2026 |
| Howard A. Doss | Director | – | – | Oct 24, 2025 |
| Donald G. Fell | Director | – | – | Oct 21, 2025 |
| Steven Dale Lee | Director | – | – | Oct 14, 2025 |
| Michael L. Peterson | Director | 200,000 | 6.53% | Jul 8, 2025 |
| Donald William Anderson | Director | 244,720 | 7.99% | Mar 25, 2025 |
| Rebecca M. Shanahan | Director | 244,720 | 7.99% | Mar 25, 2025 |
| Sajid Syed | Director | 244,720 | 7.99% | Mar 25, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Prashant Patel Chief Executive Officer, Director | Jun 22, 2026 | Option exercise | +100,000 | $0.01 | $1.00K | 282,365 |
| Surendra K. Ajjarapu Director | Jun 22, 2026 | Option exercise | +100,000 | $0.01 | $1.00K | 257,645 |
| Surendra K. Ajjarapu Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 7,882,247 |
| Prashant Patel Chief Executive Officer, Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 9,118,247 |
| Surendra K. Ajjarapu Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 7,882,247 |
| Prashant Patel Chief Executive Officer, Director | Mar 31, 2026 | Award | +5,000,000 | $0.20 | $1.00M | 9,118,247 |
| Michael L. Peterson Director | Jul 2, 2025 | Award | −200,000 | $0.90 | $180.00K | 200,000 |
| Surendra K. Ajjarapu Director | Mar 21, 2025 | Award | +600,000 | – | – | 4,463,200 |
| Surendra K. Ajjarapu Director | Mar 21, 2025 | Award | +600,000 | – | – | 3,100,000 |
| Surendra K. Ajjarapu Director | Mar 21, 2025 | Award | +2,882,247 | – | – | 1,822,247 |
| Prashant Patel Chief Strategy Officer, Director | Mar 21, 2025 | Award | +1,882,247 | – | – | 4,118,247 |
| Prashant Patel Chief Strategy Officer, Director | Mar 21, 2025 | Award | +1,500,000 | – | – | 1,500,000 |
| Prashant Patel Chief Strategy Officer, Director | Mar 21, 2025 | Award | +700,000 | – | – | 700,000 |
| Shafaat Pirani Chief Clinical Officer | Mar 21, 2025 | Award | +35,000 | – | – | 102,080 |
| Donald William Anderson Director | Mar 21, 2025 | Award | +200,000 | – | – | 244,720 |
| Rebecca M. Shanahan Director | Mar 21, 2025 | Award | +200,000 | – | – | 244,720 |
| Brian Norton Chief Executive Officer | Mar 21, 2025 | Award | +9,000,000 | – | – | 9,044,720 |
| Sajid Syed Director | Mar 21, 2025 | Award | +200,000 | – | – | 244,720 |
| Nikul Panchal Chief Pharmacy Officer | Mar 21, 2025 | Award | +90,000 | – | – | 90,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.